627 Results

FDA approves Invokana to treat diabetic kidney disease (DKD) and reduce the risk of hospitalization for heart failure in patients with type 2 diabetes and DK.- Janssen Pharma

 Added 15 days ago

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the FDA) approved a new indication for Invokana (canagliflozin) to...

CARD study of Jevtana meet primary endpoint in prostate cancer and is published in NEJM.- Sanofi

 Added 16 days ago

Data published in the New England Journal of Medicine showed that patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated...

Phase III PROfound trial of Lynparza shows efficacy in prostate cancer.- AstraZeneca + Merck Inc

 Added 16 days ago

AstraZeneca and Merck Inc. presented detailed results from the Phase III PROfound trial in 387 men with metastatic castration-resistant prostate...

Results from the second interim analysis of the phase III SPARTAN study featured in an oral presentation at ESMO 2019. Janssen Pharmaceuticals

 Added 18 days ago

The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated, longer-term results from the pivotal Phase III SPARTAN study following...

Hansa Biopharma to meet the FDA relating to imlifidase and filing requirements for the prevention of antibody mediated organ rejection.

 Added 21 days ago

Hansa Biopharma, announced that a date for a follow- up meeting with the FDA relating to imlifidase and the prevention...

CHMP recommends Bavencio + axitinib for first line treatment of renal cell carcinoma. Merck KGaA + Pfizer

 Added 26 days ago

Merck KGaA and Pfizer Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...

FDA approves Erleada for the treatment of patients with metastatic castration-sensitive prostate cancer. Johnson & Johnson

 Added 27 days ago

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the FDA has approved Erleada (apalutamide) for the treatment of...

FDA accepts BLA for enfortumab vedotin to treat bladder cancer.- Seattle Genetics.

 Added 29 days ago

Seattle Genetics, Inc announced that the FDA has accepted the Biologics License Application (BLA) for the investigational agent enfortumab vedotin...

TIVO-3 phase III trial of Fotivda shows updated overall survival in renal cell carcinoma

 Added 1 month ago

AVEO Oncology announced results from the second prespecified analysis of overall survival (OS) in the TIVO-3 trial comparing Fotivda (tivozanib)...

European Commission approves Keytruda and Inlyta combination for first line treatment of renal cell carcinoma. Merck Inc.,

 Added 1 month ago

Merck Inc., has announced that the European Commission has approved Keytruda, Merck’s anti-PD-1 therapy, in combination with Inlyta (axitinib), a...

Load more